↓ Skip to main content

Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events

Overview of attention for article published in Current Hypertension Reports, July 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

blogs
1 blog
twitter
1 X user

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
41 Mendeley
Title
Chlorthalidone: Mechanisms of Action and Effect on Cardiovascular Events
Published in
Current Hypertension Reports, July 2013
DOI 10.1007/s11906-013-0372-1
Pubmed ID
Authors

George C. Roush, Venkata Buddharaju, Michael E. Ernst, Theodore R. Holford

Abstract

How chlorthalidone (CTDN) reduces risk for cardiovascular events (CVEs) can be considered in light of its ability to lower blood pressure (BP) and its non-BP related, pleiotropic effects. The mechanism by which CTDN lowers BP is unclear but may include alterations in whole body regulation and vasodilatory actions on vasculature, possibly mediated via its inhibitory effects on carbonic anhydrase. Additionally, CTDN has potentially beneficial, non-BP related, pleiotropic effects that include improvements in endothelial function, anti-platelet activity, and oxidative status. CTDN reduces pulse wave velocity, predictor of CVEs and a measure of central aortic stiffness associated with endothelial dysfunction. On the other hand, CTDN fosters hypokalemia, hyperglycemia, sympathetic discharge, and the renin-angiotensin-aldosterone system, but these potentially harmful effects do not appear to materially reduce CTDN's ability to prevent CVEs. Further, CTDN reduces and regresses left ventricular hypertrophy (LVH), an important BP-dependent predictor of CVEs. Consistent with this finding, CTDN was more effective than amlodipine in reducing congestive heart failure (CHF) in the Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attach Trial (ALLHAT). In reducing CVEs, CTDN was superior to lisinopril in ALLHAT and superior to hydrochlorthiazide in observational cohort analyses and in network analyses of randomized trials. A statistical synthesis of randomized trials suggests that the reduction in cardiovascular risk from CTDN can be explained primarily on the basis of its ability to lower blood pressure rather than its influence upon non-BP related, pleiotropic effects.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 40 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 20%
Student > Ph. D. Student 5 12%
Student > Master 5 12%
Other 4 10%
Lecturer 3 7%
Other 5 12%
Unknown 11 27%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 7 17%
Medicine and Dentistry 6 15%
Biochemistry, Genetics and Molecular Biology 3 7%
Agricultural and Biological Sciences 3 7%
Nursing and Health Professions 3 7%
Other 6 15%
Unknown 13 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2023.
All research outputs
#4,094,752
of 23,306,612 outputs
Outputs from Current Hypertension Reports
#139
of 740 outputs
Outputs of similar age
#34,572
of 195,567 outputs
Outputs of similar age from Current Hypertension Reports
#1
of 17 outputs
Altmetric has tracked 23,306,612 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 740 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,567 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.